Xenetic Biosciences, Inc. (XBIO) News
Filter XBIO News Items
XBIO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest XBIO News From Around the Web
Below are the latest news stories about XENETIC BIOSCIENCES INC that investors may wish to consider to help them evaluate XBIO as an investment opportunity.
Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO CompensationKey Insights Xenetic Biosciences will host its Annual General Meeting on 6th of December Total pay for CEO Jeff... |
Xenetic Biosciences, Inc. Reports Third Quarter 2023 Financial ResultsEncouraging growing body of preclinical data guiding pathway to first in human trial for DNase-based oncology platformDriving development towards Phase 1 program for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid ... |
Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO ConferenceLive moderated webcast with Jeffrey Eisenberg, Chief Executive Officer of Xenetic Biosciences on Tuesday, October 24th at 1:00 PM ETFRAMINGHAM, MA / ACCESSWIRE / October 11, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), ... |
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceXenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today announced that Jeffrey Eisenberg, Chief Executive Officer of Xenetic will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY and virtually. |
Xenetic Biosciences (XBIO) Reports Q2 Loss, Tops Revenue EstimatesXenetic Biosciences (XBIO) delivered earnings and revenue surprises of 38.94% and 47.96%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Xenetic Biosciences, Inc. Reports Second Quarter 2023 Financial ResultsXenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers, today reported its financial results for the second quarter of 2023. |
Oncternal Therapeutics (ONCT) Reports Q2 Loss, Lags Revenue EstimatesOncternal Therapeutics (ONCT) delivered earnings and revenue surprises of 11.76% and 49.52%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock?Xenetic Biosciences (XBIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
Xenetic Biosciences, Inc. to Participate in the Virtual Investor Summer Spotlight SeriesXenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat oncology indications, today announced that Jeffrey Eisenberg, Chief Executive Officer and Curtis A. |
Xenetic Biosciences (NASDAQ:XBIO) Is In A Good Position To Deliver On Growth PlansEven when a business is losing money, it's possible for shareholders to make money if they buy a good business at the... |